menu
    • menu

    Company profile for Ascelia Pharma

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ascelia Pharma is a biotech company specializing in orphan oncology treatments. It focuses on developing and commercializing novel drugs that meet unmet medical needs with clear clinical and market paths. The pipeline includes two clinical-stage candidates: Orviglance? and Oncoral.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ascelia PharmaSweden Flag
    Country
    Country
    Sweden
    Address
    Address
    Hyllie Stationstorg 31 215 32 Malm
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ascelia.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/asceliapharma/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Change in Number of Shares and Votes in Ascelia Pharma AB
    Change in Number of Shares and Votes in Ascelia Pharma AB

    30 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-30/change-in-number-of-shares-and-votes-in-ascelia-pharma-ab

    PHARMIWEB
    30 Apr 2026
    Share Share
    Orviglance NDA Submitted To FDA, Pdufa Date Set For July 2026
    Orviglance NDA Submitted To FDA, Pdufa Date Set For July 2026

    09 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-09/annual-report-2025-orviglance-nda-submitted-to-the-fda-pdufa-date-set-for-july-2026

    PHARMIWEB
    09 Apr 2026
    Share Share
    Notice of Annual General Meeting in Ascelia Pharma AB
    Notice of Annual General Meeting in Ascelia Pharma AB

    30 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-30/notice-of-annual-general-meeting-in-ascelia-pharma-ab

    PHARMIWEB
    30 Mar 2026
    Share Share
    Ascelia Pharma To Present Orviglance Data At ESGAR 2026
    Ascelia Pharma To Present Orviglance Data At ESGAR 2026

    27 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-27/ascelia-pharma-announces-acceptance-of-orviglance-data-for-oral-presentation-at-the-annual-radiology

    PHARMIWEB
    27 Mar 2026
    Share Share
    Full Year & Q4 Report 2025: FDA Accepts Orviglance NDA for Review
    Full Year & Q4 Report 2025: FDA Accepts Orviglance NDA for Review

    05 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-05/full-year-and-q4-report-2025-fda-accepts-orviglance-nda-for-review

    PHARMIWEB
    05 Feb 2026
    Share Share
    Nomination Committee Appointed For AGM 2026 In Ascelia Pharma AB
    Nomination Committee Appointed For AGM 2026 In Ascelia Pharma AB

    22 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-22/nomination-committee-appointed-for-agm-2026-in-ascelia-pharma-ab

    PHARMIWEB
    22 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search